Bluejay Diagnostics, Inc. (BJDX): Nasdaq/NYSE listing notice — Bluejay Diagnostics gets Nasdaq deficiency notice for bid price below $1.00

Bluejay Diagnostics, Inc.

Received Nasdaq letter on Oct 25, 2022 for non-compliance with minimum bid price rule (NASDAQ 5550(a)(2)).
Closing bid price below $1.00 for 30 consecutive business days; 180-day cure period ends April 24, 2023.
To regain compliance, bid price must close at $1.00 or higher for at least 10 consecutive business days.
If not cured, may be eligible for additional 180 days if meeting other listing standards; otherwise subject to delisting.
Company intends to take all reasonable measures to regain compliance but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bluejay Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 25, 2022, Bluejay Diagnostics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Cap

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-067174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.